Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term metastatic colorectal-cancer. Found 12 abstracts

Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas(dagger). Annals of Oncology. 2013 Jan;24(1):257-63.   PMCID: not NIH funded
Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB, Wildes T. Senior Adult Oncology. Journal of the National Comprehensive Cancer Network. 2012 Feb;10(2):162-209.   PMCID: not NIH funded
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, Carpeno JD, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer. 2012 Oct;107(8):1277-85.   PMCID: PMC3494447
Ryabtsova O, Jansen K, Van Goethem S, Joossens J, Cheng JD, Lambeir AM, De Meester I, Augustyns K, Van der Veken P. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. Bioorganic & medicinal chemistry letters. 2012 May;22(10):3412-7.   PMCID: not NIH funded
Zhou Y, Goenaga AL, Harms BD, Zou H, Lou JL, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies. Molecular Cancer Therapeutics. 2012 Jul;11(7):1467-76.
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 Oct;123(1):19-26.   PMCID: PMC3336961 [Available on 2012/10/1]
Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, Berg DJ, McLaughlin S, Redlinger M, Dorr A, Hambleton J, Holden S, Kearns A, Kenkare-Mitra S, Lum B, Meropol NJ, O'Dwyer PJ. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2009 Dec;65(1):97-105.   PMCID: PMC2746259
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Colon Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):778-831.   PMCID: no NIH - Practice Guideline
Langer CJ, Natale RB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. SEMINARS IN ONCOLOGY. 2005 Jan;32(6):S23-S29.
Mulcahy MF, Loehrer PJ, Meropol NJ, Rademaker AW, Benson AB. A phase I study of docetaxel, cisplatin, 5-fluorouracil and leucovorin. Oncology. 2005 Jan;68 (4-6):479-84.
Dalton RR, Eisenberg BL. Surgical-Management of Recurrent Liver-Tumors. Seminars in Oncology. 1993 Oct;20(5):493-505.
Eisenberg BL, Lanciano RM, Nussbaum ML, Kleinszanto A, Taylor DD. Intraoperative Liver Radiation after Partial-Hepatectomy in a Rat Model. Journal of Surgical Research. 1992 Sep;53(3):287-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term metastatic colorectal-cancer

metastatic colorectal-cancer breast-cancer 1st-line therapy phase-ii trial growth-factor receptor chemotherapy carcinoma fluorouracil plus leucovorin oxaliplatin pancreatic-cancer trial cell lung-cancer paclitaxel NCCN Clinical Practice Guidelines inhibitor potent quality-of-life primary hepatic malignancy acute Bevacizumab Irinotecan-Pharmacokinetics-UGT 1A 1992 ristman k-jama-journal of the american medical association-v268-p57 percutaneous ethanol injection 2008 mmcdevitt j-oncology-v22-p1058 mammalian target soft-tissue sarcomas therapeutic target non-hodgkins-lymphoma 1a1 patients pts neoplasm recurrence modeling analysis older patient botulinum neurotoxin comprehensive geriatric assessment ovarian postoperative recurrence colonic neoplasms embolization adjuvant chemotherapy tumor spheroids cell-lung-cancer assessment mitomycin-c therapy in-vitro senior adult gemcitabine long-term survival progression controlled-trial antitumor-activity peptides platinum-resistant cpt-11 colony-stimulating factor pharmacodynamics regional chemotherapy factor-related oral angiogenesis inhibitor combination raf kinase dipeptidyl-peptidase-iv 1993 eilly se-journal of clinical oncology-v11-p2250 refractory comprehensive geriatric bevacizumab angiosarcoma-hemangioendotheliomas-soft tissue sarcoma intrahepatic recurrence irinotecan recurrence substrate-specificity colorectal Ovarian clinical trial serine-protease lymph-node micrometastases folinic acid resistant prostate-cancer 1987 arlson me-journal of chronic diseases-v40-p373 2008 mmcdevitt j-oncology-v22-p1060 PI3K pathway 1984 lman rs-journal of clinical oncology-v2-p1404 population 2008 pa m-j clin oncol s15-v26 arterial ugt1a polymorphisms unresectable liver metastases hepatic resection FAP Fibroblast activation protein-alpha-Seprase-DPP IV-DPP4-PREP-Prolyl oligopeptidase-Val-boroPro-PT-100-Talabostat bevacizumab zk advanced gastric-cancer prednisone plus thalidomide zk-222584 ptk elderly Circulating tumor cells mTOR disease stromal phase-iii trial 5-fluorouracil randomized epithelial cancers carcinoma patients NCCN Guidelines peripheral-blood tumor angiogenesis Oncology oral capecitabine adenocarcinoma gastric cancer phase I trials-docetaxel permeability factor carcinoma complicating cirrhosis chemotherapy axitinib-pharmacokinetics-solid tumours-non-small cell lung cancer fibroblasts oxaliplatin-based inappropriate medication use 2009 cleary naj-j clin oncol-v27-p4010 endothelial growth-factor high-dose plus bevacizumab surgery prolyl oligopeptidase toxicity predict site barrier advanced age myeloid-leukemia cancer treatment hepatocellular-carcinoma leucovorin 1994 eson bd-journal of clinical oncology-v12-p2216 tumor-growth active metabolite sn-38 neoplasm staging antigen ptk787 monoclonal-antibody AKT mini-nutritional assessment cisplatin 7-ethyl-10-hydroxycamptothecin 1st-line treatment
Last updated on Wednesday, August 12, 2020